Commissioned by Abbott Diabetes Care, this report examines the utility and impact of prescription continuous glucose monitoring (CGM) in individuals living with type 2 diabetes not using insulin. As the most common form of diabetes in the United States, type 2 is managed through lifestyle modifications, insulin, and non-insulin medications. CGM technology presents an additional disease management tool for this population.

Key findings include:

• Prevalence and management challenges: Type 2 diabetes accounts for more than 90% of diabetes cases, yet non-insulin users often have less routine blood glucose monitoring, with less rigor.
• Evolution of CGM technology: Initially designed for type 1 diabetes patients, advancements in technology now offer a broader range of applications.
• Literature-supported benefits: Growing evidence indicates that CGMs can support improved glycemic control in people living with type 2 not on insulin.
• Cost and quality-of-life considerations: Although cost and technological literacy remain considerations, early economic evaluations demonstrate promising cost-effectiveness.
• Call for broader coverage and further research: Additional studies and findings from real-world data may help further reinforce long-term benefits and real-world economic impacts.

This report was commissioned by Abbott Diabetes Care.